seasonal allergic rhinitis
Conditions
Interventions
control group:After the onset of the disease take orally Cetirizine Dihydrochloride Oral Drops for 3 weeks
Treatment group:After identification, Yuchanwei Lung Pill or Qinghe Tongjiao Oral Liquid is used for prophylaxis 2 weeks prior to the date of previous onset of disease
the onset of disease is monitored during the prophylaxis and pollen periods, and once onset of disease occurs, treatment with the drug is continued for 3 weeks.
Sponsors
Xiyuan Hospital CACMS
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: (1) Meets the diagnostic criteria for seasonal allergic rhinitis. (2) Comply with the TCM diagnosis of Lung and Spleen Qi deficiency / Lung meridian heat depletion. (3) Age between 18-70 years old male or female. (4) Disease duration of at least the last 2 years in the same season the onset of the season is basically the same and it is consistent with the allergenic pollen transmission period. (4) The disease has developed in the same season for at least the past 2 years the season of onset is basically the same and is consistent with the allergenic pollen transmission period. (5) Allergen testing at least one seasonal allergen is positive. (6) Informed consent and voluntary testing.
Exclusion criteria
Exclusion criteria: 1) Post upper respiratory tract infection rhinitis, eosinophilia, vasodilatory rhinitis, bronchitis, Pneumonia, asthma. (2) Pregnant or breastfeeding women or women of childbearing age who are unable to use effective contraception during the study period. (3) Severe primary cardiac, hepatic, pulmonary, renal, haematological diseases and diabetes mellitus or other serious diseases affecting their survival. serious illness. (4) Persons who are unable to give full informed consent due to intellectual or behavioural disabilities. (5) Suspected or confirmed history of alcohol or drug abuse. (6) Use of medications for the treatment of AR (e.g., glucocorticoids in any form, antihistamines, antileukotrienes, anticholinergics) within the previous week, antileukotrienes, anticholinergics, Chinese herbal tonics, Chinese herbal granules, proprietary Chinese medicines, etc.). (7) Acceptance of other clinical trials within 30 days. (8) Known allergy, intolerance or contraindication to the drugs related to this study. (9) Those who have a combination of obvious other evidence types in the diagnosis, such as renal yang deficiency, blood stasis, etc..
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Nasal symptoms scored on a visual analogue quantitative scale; | — |
Secondary
| Measure | Time frame |
|---|---|
| Rhinoconjunctivitis-related quality of life questionnaire scores; | — |
Countries
China
Contacts
Public ContactLi Lei
Xiyuan Hospital CACMS
Outcome results
None listed